Malarone

Phase 1Small molecule

Medicines for Malaria Venture

Malarone is one of 61 small molecule programs targeting Plasmodium falciparum malaria. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plasmodium Falciparum MalariaActive, not recruiting

MalariaActive, not recruiting

Plasmodium Falciparum MalariaPhase 1

Active, not recruiting

MalariaPreclinical

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

1 2

Stelara

Johnson & Johnson

Preclinical

—3

Hydroxychloroquine Sulfate

Novartis

Preclinical

—4

Iron

WWatson Pharmaceuticals

Preclinical

1 5

Malarone

Medicines for Malaria Venture

Phase 1

3 6

IV LBH589

Novartis

Preclinical

1 7

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 8

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Piperaquine

UUniversity of Oxford

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria3 trials

Safety and Efficacy Study of IV Artesunate to Treat Malaria

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT00298610·30 enrolled

Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Completed·RRadboud University Medical Center·N/A·NCT01236612·25 enrolled

Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT01150344·317 enrolled

Plasmodium Falciparum2 trials

Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis

Completed·RRadboud University Medical Center·N/A·NCT01422954·20 enrolled

Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Completed·RRadboud University Medical Center·N/A·NCT01218893·30 enrolled

Plasmodium falciparum malaria1 trial

DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria

Completed· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 1·NCT02450578·22 enrolled

Stress1 trial

Malarone Pharmacokinetics Under Simulated Physiologic Stressors of Deployment

Withdrawn·WWalter Reed Army Institute of Research (WRAIR)·Phase 4·NCT03991208

AIN1 trial

Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites

Completed·RRadboud University Medical Center·N/A·NCT01660854·21 enrolled

1 more indication

Unspecified1 trial

Atoguanil BA Study

Completed· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 1·NCT04866602·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Malarone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Malarone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Malarone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medicines for Malaria Venture company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Medicines for Malaria Venture

Malarone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria3 trials

Plasmodium Falciparum2 trials

Plasmodium falciparum malaria1 trial

Stress1 trial

AIN1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News